What is SciSparc acquiring from Xylo Technologies?

SciSparc plans to acquire a portfolio of patents, trademarks, and intellectual property related to endoscopic systems and medical cameras, including the MUSE™ device targeting GERD treatments, pending definitive agreements.

How big is the market SciSparc is targeting with this acquisition?

The global GERD device market was valued at about $2.5 billion in 2024 and is projected to reach approximately $3.03 billion by 203,0 according to market research predictions.

Why did SciSparc’s stock fall after the acquisition announcement?

SciSparc’s share price fell significantly following the announcement as investors reacted to dilution risks from issuing shares and uncertainty about execution, common in micro‑cap transactions of this nature.

US Stocks

SciSparc to Acquire Endoscopic Device Patents Targeting $3B Market

ByAmna Habib January 13, 2026January 13, 2026

SciSparc, a clinical‑stage pharmaceutical and technology company listed on Nasdaq under the ticker SPRC, recently made waves in the medical device arena by announcing plans to acquire a treasury of patents and intellectual property for innovative endoscopic systems and medical cameras, including the MUSE™ endoscopic system. This strategic move targets a rapidly growing global market for devices used in minimally invasive procedures to treat conditions such as gastroesophageal reflux disease (GERD), potentially tapping into a $3 billion market opportunity by 2030.